Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

  • Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter.
  • The Journal mentioned that the deal could be one of the largest takeovers of the year.
  • The Wall Street Journal reported last week that Merck was in talks to buy Seagen, which would bolster the pharma giant's cancer-drug portfolio, but no agreement was imminent. 
  • Related: SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know.
  • The talks have picked up the pace. The companies are scheduled to meet this week, some people said.
  • WSJ could not tell if Merck had already submitted a formal offer for Seagen. 
  • Merck may not be the only suitor, with others also eyeing the cancer-focused biotech, some people told WSJ.
  • The WSJ report notes the tricky nature of the deal, given the heightened risk of a regulatory challenge. 
  • Through a 2020 deal, Merck acquired 5 million shares of Seagen for $1 billion. It also paid $600 million upfront for Seagen's LIV-1-targeting antibody-drug conjugates, including the most advanced ladiratuzumab vedotin for breast cancer and other solid tumors.
  • The companies have also teamed up on Seagen's HER2 small molecule drug Tukysa. Merck holds Tukysa rights in Asia, the Middle East, and Latin America.
  • Price Action: SGEN shares are up 3.45% at $180.00, and MRK stock is down 0.25% at $91.77 during the premarket session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.